Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

173 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse.
Sternberg CN, Yagoda A, Scher HI, Watson RC, Geller N, Herr HW, Morse MJ, Sogani PC, Vaughan ED, Bander N, et al. Sternberg CN, et al. Among authors: bander n. Cancer. 1989 Dec 15;64(12):2448-58. doi: 10.1002/1097-0142(19891215)64:12<2448::aid-cncr2820641209>3.0.co;2-7. Cancer. 1989. PMID: 2819654
Chemotherapeutic management of invasive bladder carcinoma.
Sternberg CN, Yagoda A, Scher HI, Watson RC, Herr HW, Morse MJ, Sogani PC, Vaughan ED, Bander N, Geller N, et al. Sternberg CN, et al. Among authors: bander n. Eur Urol. 1988;14 Suppl 1:19-20. doi: 10.1159/000473033. Eur Urol. 1988. PMID: 3053199 Clinical Trial. No abstract available.
Phase I/II trial of intravesical methotrexate for superficial bladder tumors.
Sternberg CN, Yagoda A, Bander NH, Whitmore WF Jr, Huffman JL, Fleisher M, Melamed M, Fanucchi MP, Hollander P, Vaughan ED Jr. Sternberg CN, et al. Among authors: bander nh. Cancer Chemother Pharmacol. 1986;18(3):265-9. doi: 10.1007/BF00273400. Cancer Chemother Pharmacol. 1986. PMID: 3802383
Phase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer.
Tagawa ST, Milowsky MI, Morris M, Vallabhajosula S, Christos P, Akhtar NH, Osborne J, Goldsmith SJ, Larson S, Taskar NP, Scher HI, Bander NH, Nanus DM. Tagawa ST, et al. Clin Cancer Res. 2013 Sep 15;19(18):5182-91. doi: 10.1158/1078-0432.CCR-13-0231. Epub 2013 May 28. Clin Cancer Res. 2013. PMID: 23714732 Free PMC article. Clinical Trial.
A Phase I/II Study for Analytic Validation of 89Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer.
Pandit-Taskar N, O'Donoghue JA, Durack JC, Lyashchenko SK, Cheal SM, Beylergil V, Lefkowitz RA, Carrasquillo JA, Martinez DF, Fung AM, Solomon SB, Gönen M, Heller G, Loda M, Nanus DM, Tagawa ST, Feldman JL, Osborne JR, Lewis JS, Reuter VE, Weber WA, Bander NH, Scher HI, Larson SM, Morris MJ. Pandit-Taskar N, et al. Among authors: bander nh. Clin Cancer Res. 2015 Dec 1;21(23):5277-85. doi: 10.1158/1078-0432.CCR-15-0552. Epub 2015 Jul 14. Clin Cancer Res. 2015. PMID: 26175541 Free PMC article. Clinical Trial.
Newer diagnostic techniques for bladder cancer.
Carter HB, Amberson JB, Bander NH, Badalament R, Gorelick J, Vaughan ED Jr, Whitmore WF Jr. Carter HB, et al. Among authors: bander nh. Urol Clin North Am. 1987 Nov;14(4):763-9. Urol Clin North Am. 1987. PMID: 3314067 Review.
Phase 1/2 multiple ascending dose trial of the prostate-specific membrane antigen-targeted antibody drug conjugate MLN2704 in metastatic castration-resistant prostate cancer.
Milowsky MI, Galsky MD, Morris MJ, Crona DJ, George DJ, Dreicer R, Tse K, Petruck J, Webb IJ, Bander NH, Nanus DM, Scher HI. Milowsky MI, et al. Urol Oncol. 2016 Dec;34(12):530.e15-530.e21. doi: 10.1016/j.urolonc.2016.07.005. Epub 2016 Oct 17. Urol Oncol. 2016. PMID: 27765518 Free PMC article. Clinical Trial.
173 results